Recent Updates
Recently added Catalysts
PBM Positive Sentiment Score: 70/100

Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase

Friday, May 17, 2024 1 min read
Key Takeaway: Psyence Biomedical Ltd (Nasdaq: PBM) has announced its participation in the A.G.P. Virtual Healthcare Company Showcase, scheduled for May 21, 2024. Management will engage in 1x1 meetings with investors, aiming to promote the company's focus on developing psilocybin-based psychedelic medicines for mental health disorders. Psyence Biomed is recognized as the first life science biotechnology company in the world traded on Nasdaq, emphasizing an evidence-based approach to psychedelic therapeutics.

Market Sentiment Analysis

POSITIVE FACTORS

  • Psyence Biomed is participating in a prominent healthcare showcase, enhancing visibility.
  • Management's 1x1 meetings with investors could lead to new funding opportunities.
  • Focus on psilocybin-based psychedelic medicines positions Psyence favorably in a growing market.

Full Press Release Details

NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that management will host 1x1 meetings with investors during the A.G.P. Virtual Healthcare Company Showcase, which is being held May 21, 2024.
For more information, or to register: https://allianceg.com/events/.
About Psyence Biomed
Psyence Biomedical Ltd., a corporation organized under the laws of Ontario, Canada, is the world’s first life science biotechnology company traded on The Nasdaq Stock Market LLC (“Nasdaq”) (Nasdaq:PBM) that is focused on the development of botanical (nature derived, or non-synthetic) psilocybin-based psychedelic medicines. The name “Psyence” combines the words “psychedelics” and “science” to affirm Psyence Biomed’s commitment to an evidence-based approach to innovation as it works to develop safe and effective, nature-derived psychedelic therapeutics to treat a broad range of mental health disorders. Psyence Biomed is initially focused on mental health disorders in the context of Palliative Care.
Learn more at www.psyencebiomed.com and on LinkedIn.
Email: ir@psyencebiomed.com
Media Inquiries: media@psyencebiomed.com
General Information: info@psyencebiomed.com
Phone: +1 416-477-1708
jfeffer@lifesciadvisors.com

Frequently Asked Questions

When will Psyence Biomed hold investor meetings?

Psyence Biomed will host 1x1 investor meetings during the A.G.P. Virtual Healthcare Showcase on May 21, 2024.

What is Psyence Biomed's focus?

Psyence Biomed specializes in developing botanical, psilocybin-based psychedelic medicines for mental health.

What distinguishes Psyence Biomed in the market?

Psyence Biomed is the first life science biotech company traded on Nasdaq, focused on psychedelic therapies.

How can I contact Psyence Biomed?

You can contact Psyence Biomed via email at ir@psyencebiomed.com or call +1 416-477-1708.

Where can I learn more about Psyence Biomed?

Visit www.psyencebiomed.com or check their LinkedIn for more information.

Tags: PBM Viatris Investor Conferences Healthcare Psyence Biomed psilocybin mental health A.G.P. Showcase
Last updated: May 17, 2024